Health matrix (Cleveland, Ohio : 1991)最新文献_第5页

Nanotechnology: using co-regulation to bring regulation of modern technologies into the 21st century. 纳米技术:利用协同监管将现代技术的监管带入21世纪。

Health matrix (Cleveland, Ohio : 1991) Pub Date : 2013-01-01

Michelle Reese

引用次数: 0

Asking the right questions: body scanners, is salus populi supreme lex the answer? 问正确的问题:人体扫描仪，salus populi supreme lex是答案吗?

Health matrix (Cleveland, Ohio : 1991) Pub Date : 2013-01-01

Victoria Sutton

引用次数: 0

The moral from Sorrell: educate, don't legislate. 索雷尔的寓意是:教育，而不是立法。

Health matrix (Cleveland, Ohio : 1991) Pub Date : 2013-01-01

George R Gooch, J James Rohack, Marisa Finley

{"title":"The moral from Sorrell: educate, don't legislate.","authors":"George R Gooch, J James Rohack, Marisa Finley","doi":"","DOIUrl":"","url":null,"abstract":"This Article argues that in response to the United States Supreme Court's 2011 decision in Sorrell v. IMS Health Inc., state legislators should refrain from enacting prescription confidentiality laws and instead implement policies supporting academic detailing, a form of continuing medical education in which trained health professionals such as physicians, registered nurses, advanced practice nurses, and pharmacists provide evidence-based information about prescription drugs to prescribers. According to Sorrell, pharmaceutical companies may freely use physicians' prescribing data to better promote, or \"detail,\" products to physicians without government interference. While pharmaceutical companies may profit from detailing drugs to physicians, detailing increases health care costs for patients and negatively affects patient health outcomes. These problems motivated Maine, New Hampshire, and Vermont to enact prescription confidentiality laws that banned the use of information about the prescribing habits of physicians to help market drugs to physicians. Recent state attempts to stop drug detailing to physicians have been found to violate the First Amendment. This Article provides a history and background on the pharmaceutical-detailing process and analyzes recent legal decisions relating to prescription confidentiality. It concludes that academic detailing is a viable solution to the negative effects of pharmaceutical detailing and is consistent with the First Amendment.","PeriodicalId":73212,"journal":{"name":"Health matrix (Cleveland, Ohio : 1991)","volume":"23 1","pages":"237-77"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31540102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India. 探索强制许可作为印度抗逆转录病毒药物的有效政策工具。

Health matrix (Cleveland, Ohio : 1991) Pub Date : 2013-01-01

Dipika Jain, Jonathan J Darrow

引用次数: 0

The patent eligibility of diagnostic methods after Prometheus: a redefined test for transformation. 普罗米修斯之后诊断方法的专利资格:一种重新定义的转化测试。

Health matrix (Cleveland, Ohio : 1991) Pub Date : 2013-01-01

Scott Frederick Peachman

引用次数: 0

Challenging the FDA's authority to regulate autologous adult stem cells for therapeutic use: Celltex therapeutics' partnership with RNL Bio, substantial medical risks, and the implications of United States v. Regenerative Sciences. 挑战FDA监管自体成体干细胞治疗用途的权威:Celltex therapeutics与RNL Bio的合作、重大医疗风险以及United States诉Regenerative Sciences的影响。

Health matrix (Cleveland, Ohio : 1991) Pub Date : 2013-01-01

Katherine Drabiak-Syed

{"title":"Challenging the FDA's authority to regulate autologous adult stem cells for therapeutic use: Celltex therapeutics' partnership with RNL Bio, substantial medical risks, and the implications of United States v. Regenerative Sciences.","authors":"Katherine Drabiak-Syed","doi":"","DOIUrl":"","url":null,"abstract":"This Article examines the convergence of three corporations that have attempted to capitalize on translating emerging research into clinical procedures by manufacturing and facilitating the process for patients to obtain mesenchymal stem cell (MSC) injections. Although the Food and Drug Administration (FDA) has asserted its authority to regulate somatic cell therapy products like MSCs under the Public Health Service Act and the Food, Drug, and Cosmetic Act, some manufacturers have attempted to circumvent FDA regulation through various mechanisms and argue that their products do not fall within the definition of a biological product or drug. However, scientific knowledge of using MSCs for clinical therapy remains in its infancy, and MSCs pose a number of serious risks to patients. This Article focuses on the development of Celltex, a company based in Sugar Land, Texas that manufactures and facilitates the injection of autologous MSCs; RNL Bio, a company that licenses its operations technology to Celltex; and Regenerative Sciences, a company based in Broomfield, Colorado that was recently involved in litigation with the FDA. Corporate circumvention of intended regulatory oversight exposes patients to potentially inefficacious products that could contribute to serious medical injuries such as viruses, myocardial infarction, cancer, or death.","PeriodicalId":73212,"journal":{"name":"Health matrix (Cleveland, Ohio : 1991)","volume":"23 2","pages":"493-535"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31956446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The goals of FDA regulation and the challenges of meeting them. FDA法规的目标和实现这些目标的挑战。

Health matrix (Cleveland, Ohio : 1991) Pub Date : 2013-01-01

Ralph S Tyler

引用次数: 0

When oil attacks: litigation options for Nigerian plaintiffs in U.S. federal courts. 当石油袭击:尼日利亚原告在美国联邦法院的诉讼选择。

Health matrix (Cleveland, Ohio : 1991) Pub Date : 2013-01-01

Lauren McCaskill

引用次数: 0

Safeguards for mentally disabled respondents in removal proceedings. 在递解诉讼中为智障答辩人提供的保障。

Health matrix (Cleveland, Ohio : 1991) Pub Date : 2013-01-01

Christina P Greer